William Gibson, OD
Optometrist · Louisville, KYNPI 1679190060
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 25.5% of the total. Among optometrist clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $33.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$2K
- Sun Pharmaceutical Industries Inc.$1K
- AbbVie$514
- Novartis$452
- Bausch & Lomb Americas Inc.$398
- Oyster Point Pharma, Inc.$325
- plus $2K from 18 others
What the payments were for
- Food & beverage$6,471100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 39 | $1,653 |
| Sun Pharmaceutical Industries Inc. | 30 | $1,147 |
| AbbVie(2 entities) | 18 | $514 |
| Novartis | 23 | $452 |
| Bausch & Lomb Americas Inc. | 15 | $398 |
| Oyster Point Pharma, Inc. | 12 | $325 |
| Harrow Eye, LLC | 7 | $282 |
| Amgen(2 entities) | 10 | $279 |
| Dompe US, Inc. | 9 | $270 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $221 |
| Alcon | 4 | $194 |
| Johnson & Johnson Vision Care, Inc. | 1 | $130 |
| Glaukos Corporation | 1 | $128 |
| Coopervision Inc. | 1 | $95 |
| Biotissue Holdings Inc. | 4 | $79 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $61 |
| Aerie Pharmaceuticals, Inc. | 3 | $48 |
| Rxsight Inc | 2 | $45 |
| Astellas Pharma US Inc | 2 | $40 |
| Carl Zeiss Meditec, Inc. | 1 | $33 |
| Kala Pharmaceuticals, Inc. | 2 | $29 |
| Sight Sciences, Inc. | 1 | $23 |
| Alimera Sciences, Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,489 in reported general payments places this provider in the 95th percentile of 712 optometrist providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 136 | $251,846 |
| XiidraLifitegrast | 43 | $63,730 |
| RestasisCyclosporine | 33 | $46,688 |
| CequaCyclosporine | 57 | $38,893 |
| TyrvayaVarenicline Tartrate | 40 | $25,795 |
| Loteprednol Etabonate | 77 | $9,518 |
| Cyclosporine | 18 | $8,783 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 172 | $6,719 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $4,405 |
| Prednisolone Acetate | 111 | $3,634 |
| Travoprost | 11 | $1,790 |
| Latanoprost | 111 | $1,260 |
| Brimonidine Tartrate | 45 | $1,256 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $857 |
| Doxycycline Monohydrate | 37 | $773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,653 | $251,846136 claims |
| Bausch & Lomb Americas Inc.Xiidra | $398 | $63,73043 claims |
| AbbVieRestasis | $514 | $46,68833 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,147 | $38,89357 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $325 | $25,79540 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $61 | $9,51877 claims |
| AlconSimbrinza | $194 | $4,40522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 712 optometrist providers in Kentucky.
Other optometrist in Louisville
- Lee PeplinskiLouisville$74K
- Austin LifferthLouisville$72K
- Aaron McNultyLouisville$22K
- Ian McWherterLouisville$18K
- Kevin SnipesLouisville$13K
- Richard ManganLouisville$12K
- Keith SlaydenLouisville$9K
- Benjamin PaxtonLouisville$8K
- Nikolaos ZagorianosLouisville$8K
- Fiona BoakLouisville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.